Tentarix Biotherapeutics

AbbVie Inc. and Tentarix Biotherapeutics today announced a multi-year collaboration focused on the discovery and development of conditionally-active, multi-specific biologic candidates in oncology and immunology.

Gilead Sciences, Inc. and Tentarix Biotherapeutics today announced that the companies established three multi-year collaborations leveraging Tentarix’s proprietary Tentacles platform to discover and develop multi-functional, conditional protein therapeutics for oncology and inflammatory diseases.

The page covers Tentarix news, including partnerships with Gilead and AbbVie, $132M in financing, and executive team updates for its conditionally active biologics platform.

Tentarix Biotherapeutics today announced the appointment of Andrew Kidd, MD, as chief executive officer. Mr. Kidd joins Tentarix with a distinguished career of over two decades of executive and biotech experience.

Join Tentarix in San Diego. Help develop conditionally active biologics for oncology and autoimmune disease. Excellent benefits, equity, mission-driven team.

The page introduces Tentarix's leadership team and names Versant, Samsara, Amplitude, and Gilead as investors backing the next generation of biologics.

The page provides contact information for Tentarix Biotherapeutics at its San Diego headquarters for partnership, collaboration, or investor relations inquiries.

Tentarix develops conditionally active multispecific biologics with high therapeutic index for oncology and autoimmune disease. Based in San Diego.

Tentarix's privacy policy describes how it uses information submitted through www.tentarix.com and says it applies only to that website. The policy may be updated, with changes posted on the page.